CDK4 and breast cancer: Consistent with the above reported observations that RB1 pathway disruption is correlated with resistance to therapies that function through cytostatic mechanisms, such as hormone therapy, reactivation of the antiproliferative activity of RB1 through CDK4/6 inhibitors in combination with endocrine therapy have shown promise in breast cancer clinical trials [137].